仟源醫藥(300254.SZ):老撾藥企委託嘉逸醫藥生產默藥仿製藥物質實體
格隆匯2月18日丨仟源醫藥(300254.SZ)公佈,2022年2月18日公司召開第四屆董事會第二十九次會議,審議通過了《關於控股子公司嘉逸醫藥簽署<委託加工合作協議>的議案》,同意嘉逸醫藥與老撾製藥企業Laos Alliance Pharmaceutical Group Co.,Ltd.簽署《委託加工合作協議》,Laos Alliance Pharmaceutical Group Co.,Ltd.擬委託嘉逸醫藥生產抗新冠藥品MOLNUPIVIR仿製藥的物質實體。該協議簽署完成後,合作雙方將分別向所在地藥品監管部門申請該次藥品物質實體委託生產事項的許可/備案。
該協議的簽署是Laos Alliance Pharmaceutical Group Co.,Ltd.對嘉逸醫藥生產默藥仿製藥物質實體生產能力和質量控制能力的認可,有利於加快公司的國際化戰略佈局,提升公司的盈利水平,促進公司持續、健康、穩步發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.